奥氮平和奋乃静治疗首发精神分裂症患者疗效比较

目的比较奥氮平和奋乃静治疗首发精神分裂症患者的临床疗效。方法 112例首发精神分裂症患者分为观察组和对照组,每组56例,对照组患者接受奋乃静片治疗,观察组患者给予奥氮平治疗,分别于治疗前和治疗12周后进行临床疗效评价、阳性和阴性症状量表(PANSS)和威斯康星卡片分类测验(WCST)测评,比较2组患者的临床疗效和认知功能。结果治疗前2组患者PANSS总分及各因子分比较差异均无统计学意义(P>0.05);治疗后2组患者PANSS总分及各因子分均较治疗前降低,差异有统计学意义(P<0.05);治疗后2组PANSS总分和阴性因子分比较差异有统计学意义(P<0.05)。治疗前2组患者WCST各维度比较差异均无统计学意义(P>0.05);治疗后观察组患者WCST各维度均显著优于对照组,差异有统计学意义(P<0.05);2组患者治疗后WCST各维度与治疗前比较差异均有统计学意义(P<0.05)。2组患者临床治疗效果和不良反应发生率比较差异均无统计学意义(P>0.05)。结论奥氮平治疗首发精神分裂症临床疗效确切,总体疗效和不良反应与奋乃静相当;但奥氮平更能够有效改善精神分裂症患者的认知功能。

Comparison of effect of olanzapine and perphenazine in treatment for patients with first-episode schizophrenia

Objective To compare the clinical effect of olanzapine and perphenazine in treatment for patients with firstepisode schizophrenia. Methods A total of 112 patients with first-episode schizophrenia were divided into observation group and control group,56 cases in each group. The patients in control group were treated with perphenazine tablets,and the patients in observation group were treated with olanzapine. All patients were evaluated by clinical effects, positive and negative symptoms scale（PANSS） and Wisconsin card sorting test（WCST） before and 12 weeks after treatment respectively. The clinical curative effect and cognitive function were compared between the two groups, Results There was no significant difference in PANSS total score and factor scores between the two groups before treaunent （ P 〉 O. 05 ）. The PANSS total score and factor scores after treatment were significantly lower than those before treatment（ P 〈 0.05 ）. There was significant difference in PANSS total score and factor scores between the two groups after treatment（P 〈 0.05 ）. There was no significant difference in each dimension of WCST between the two groups before treatment（ P 〉 0. 05 ）. The dimensions of WCST in observation group were significantly improved than those in control group after treatment（P 〈0.05 ）. There were significant differences in the dimensions of WCST before and after treatment in the two groups（P 〈0.05）. There was no significant difference in the therapeutic efficacy and incidence rate of adverse reactions between the two groups（ P 〉 0.05 ）. Conclusion Olanzapine for treating patients with first-episode schizophrenia can obtain preonunced curative effect, and the total effects and adverse reactions were equivalent to perphenazine;but olanzapine can effectively improve the cognitive function of patients with schizophrenia.